How Curanex Pharma’s Q3 Loss Spurs Urgent Funding Push & Pipeline ExpansionRead how Curanex Pharmaceuticals’ Q3 2026 results reveal deep financial strain, a reverse split, and a push into oncology to secure future funding.CURANEX PHARMACEUTICALS INC Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 14/11/2026, 17:28 2 minutes to read